Moderna, Inc. (MRNA) stock
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Earnings
Moderna's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Moderna's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 12, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 6, 2026before the open | $1.30B | +30.0% | $0.38 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 31, 2026before the open | $145.00M | +2.1% | -$1.97 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 1, 2026before the open | $389.00M | +260.2% | -$3.40 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 13, 2026before the open | $678.00M | -32.2% | -$2.11 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $1.00B | -47.4% | -$0.51 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 1, 2025before the open | $142.00M | -41.1% | -$2.13 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025before the open | $108.00M | -35.3% | -$2.52 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 14, 2025before the open | $1.00B | -64.3% | -$2.91 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $1.90B | +5.6% | $0.03 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024before the open | $241.00M | -29.9% | -$3.33 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $167.00M | -91.2% | -$3.07 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $2.80B | -45.1% | $0.55 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $1.80B | – | -$9.53 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $344.00M | -92.7% | -$3.62 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $1.90B | -68.9% | $0.19 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | $5.10B | -29.2% | $3.61 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022before the open | $4.70B | – | $5.24 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $6.10B | – | $8.58 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $7.20B | – | $11.29 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $5.00B | – | $7.70 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 13, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Moderna's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue growth | FY2026 | +10% | +10% | Reaffirmed | Jul 31, 2026 |
| total revenue growth | FY2026 | +15% – +25% | +10% | Raised | Nov 6, 2026 |
| Capital expenditures | FY2026 | $200.00M | $200.00M – $300.00M | Lowered | Nov 6, 2026 |
| Capital expenditures | FY2026 | $200.00M – $300.00M | $200.00M – $300.00M | Reaffirmed | Jul 31, 2026 |
| cash and investments | FY2026 | $8.10B – $8.30B | – | Raised | Nov 6, 2026 |
| Cost of sales | FY2026 | $1.70B | $900.00M | Lowered | Nov 6, 2026 |
| Cost of sales | FY2026 | $1.70B | $1.80B | Lowered | Jul 31, 2026 |
| estimated GAAP operating costsGAAP | FY2026 | $5.40B – $5.70B | – | New | May 1, 2025 |
| GAAP operating expensesGAAP | FY2026 | $4.90B | – | New | Jan 12, 2026 |
| potential cash cost savings | FY2026 | $500.00M | – | New | Jan 13, 2025 |
| Research and development expenses | FY2026 | $2.70B | $3.00B | Raised | Nov 6, 2026 |
| Research and development expenses | FY2026 | $2.90B | $3.00B | Raised | Jul 31, 2026 |
| Selling, general and administrative expenses | FY2026 | $1.00B | $1.00B | Lowered | Nov 6, 2026 |
| Selling, general and administrative expenses | FY2026 | $1.00B | $1.00B | Lowered | Jul 31, 2026 |
| Year-end cash and investments | FY2026 | $4.70B – $5.20B | $4.50B – $5.00B | Raised | Jul 31, 2026 |
| Year-end cash and investments | FY2026 | $5.50B – $6.00B | – | Raised | Feb 13, 2026 |
| annual sales | FY2027 | $8.00B – $15.00B | – | New | May 4, 2023 |
| GAAP operating cost estimateGAAP | FY2027 | $4.70B – $5.00B | – | New | May 1, 2025 |
| GAAP operating expensesGAAP | FY2027 | $4.20B – $4.60B | – | New | Jan 12, 2026 |
Guidance vs results
The last range Moderna gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $1.90B | $1.93BΣ4Q | Above range |
| Q2 FY2023 | Revenue | $200.00M – $300.00M | $344.00M | Above range |
Guidance history
Every forecast Moderna put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 6, 2026 | Capital expenditures | FY2026 | $200.00M | Lowered |
| Nov 6, 2026 | Cost of sales | FY2026 | $1.70B | Lowered |
| Nov 6, 2026 | Research and development expenses | FY2026 | $2.70B | Raised |
| Nov 6, 2026 | Selling, general and administrative expenses | FY2026 | $1.00B | Lowered |
| Nov 6, 2026 | cash and investments | FY2026 | $8.10B – $8.30B | Raised |
| Nov 6, 2026 | total revenue growth | FY2026 | +15% – +25% | Raised |
| Jul 31, 2026 | Capital expenditures | FY2026 | $200.00M – $300.00M | Reaffirmed |
| Jul 31, 2026 | Cost of sales | FY2026 | $1.70B | Lowered |
| Jul 31, 2026 | Research and development expenses | FY2026 | $2.90B | Raised |
| Jul 31, 2026 | Selling, general and administrative expenses | FY2026 | $1.00B | Lowered |
| Jul 31, 2026 | Year-end cash and investments | FY2026 | $4.70B – $5.20B | Raised |
| Jul 31, 2026 | revenue growth | FY2026 | +10% | Reaffirmed |
| May 1, 2026 | Capital expenditures | FY2026 | $200.00M – $300.00M | New |
| May 1, 2026 | Cost of sales | FY2026 | $1.80B | New |
| May 1, 2026 | Research and development expenses | FY2026 | $3.00B | Raised |
| May 1, 2026 | Selling, general and administrative expenses | FY2026 | $1.00B | Lowered |
| May 1, 2026 | Year-end cash and investments | FY2026 | $4.50B – $5.00B | Raised |
| May 1, 2026 | revenue growth | FY2026 | +10% | Reaffirmed |
| Feb 13, 2026 | Capital expenditures | FY2026 | $200.00M – $300.00M | New |
| Feb 13, 2026 | Cost of sales | FY2026 | $900.00M | Raised |
| Feb 13, 2026 | Research and development expenses | FY2026 | $3.00B | Raised |
| Feb 13, 2026 | Selling, general and administrative expenses | FY2026 | $1.00B | Lowered |
| Feb 13, 2026 | Year-end cash and investments | FY2026 | $5.50B – $6.00B | Raised |
| Feb 13, 2026 | Revenue | FY2026 | +10% | New |
| Jan 12, 2026 | expected GAAP operating expenses | FY2025 | $5.00B – $5.20B | Lowered |
| Jan 12, 2026 | GAAP operating expenses | FY2026 | $4.90B | New |
| Jan 12, 2026 | GAAP operating expenses | FY2027 | $4.20B – $4.60B | New |
| Jan 12, 2026 | revenue | FY2025 | $1.90B | Narrowed |
| Jan 12, 2026 | revenue growth | FY2026 | +10% | New |
| Nov 6, 2025 | Capital Expenditures | FY2025 | $300.00M | Reaffirmed |
| Nov 6, 2025 | Cost of Sales | FY2025 | $800.00M – $900.00M | Lowered |
| Nov 6, 2025 | Research and Development Expenses | FY2025 | $3.30B – $3.40B | Raised |
| Nov 6, 2025 | Selling, General and Administrative Expenses | FY2025 | $1.10B | Lowered |
| Nov 6, 2025 | Cash and Investments | FY2025 | $6.50B – $7.00B | Raised |
| Nov 6, 2025 | Revenue | FY2025 | $1.60B – $2.00B | Narrowed |
| Aug 1, 2025 | Capital expenditures | FY2025 | $300.00M | New |
| Aug 1, 2025 | expected GAAP operating expenses | FY2025 | $5.90B – $6.10B | New |
| Aug 1, 2025 | Year-end cash and investments | FY2025 | $6.00B | Raised |
| Aug 1, 2025 | Selling, general and administrative expenses | FY2025 | $1.10B | Lowered |
| Aug 1, 2025 | research and development expenses | FY2025 | $3.60B – $3.80B | Raised |
| Aug 1, 2025 | Cost of sales | FY2025 | $1.20B | New |
| Aug 1, 2025 | projected revenue | FY2025 | $1.50B – $2.20B | New |
| May 1, 2025 | Capital expenditures | FY2025 | $400.00M | Reaffirmed |
| May 1, 2025 | GAAP operating cost estimate | FY2027 | $4.70B – $5.00B | New |
| May 1, 2025 | Cost of sales | FY2025 | $1.20B | Lowered |
| May 1, 2025 | Year-end cash and investments | FY2025 | $6.00B | Raised |
| May 1, 2025 | Selling, general and administrative expenses | FY2025 | $1.10B | Lowered |
| May 1, 2025 | research and development expenses | FY2025 | $4.10B | Raised |
| May 1, 2025 | estimated GAAP operating costs | FY2026 | $5.40B – $5.70B | New |
| May 1, 2025 | revenue | FY2025 | $200.00M | Lowered |
| May 1, 2025 | expected revenue | FY2025 | $1.50B – $2.50B | Raised |
| Feb 14, 2025 | Capital expenditures | FY2025 | $400.00M | New |
| Feb 14, 2025 | research and development expenses | FY2025 | $4.10B | Raised |
| Feb 14, 2025 | Year-end cash and investments | FY2025 | $6.00B | Raised |
| Feb 14, 2025 | Selling, general and administrative expenses | FY2025 | $1.10B | Lowered |
| Feb 14, 2025 | Cost of sales | FY2025 | $1.20B | Lowered |
| Feb 14, 2025 | revenue | FY2025 | $200.00M | Lowered |
| Feb 14, 2025 | expected revenue | FY2025 | $1.50B – $2.50B | Reaffirmed |
| Jan 13, 2025 | potential cash cost savings | FY2026 | $500.00M | New |
| Jan 13, 2025 | cash and investments | FY2025 | $6.00B | Raised |
| Jan 13, 2025 | cash cost reductions | FY2025 | $1.00B | Lowered |
| Jan 13, 2025 | revenue | FY2025 | $1.50B – $2.50B | New |
| Nov 7, 2024 | Capital expenditures | FY2024 | $1.20B | Raised |
| Nov 7, 2024 | Cost of sales | FY2024 | 40% – 45% | New |
| Nov 7, 2024 | research and development expenses | FY2024 | $4.60B – $4.70B | Lowered |
| Nov 7, 2024 | Selling, general and administrative expenses | FY2024 | $1.20B | Lowered |
| Nov 7, 2024 | expected net product sales | FY2024 | $3.00B – $3.50B | Reaffirmed |
| Aug 1, 2024 | Capital expenditures | FY2024 | $900.00M | Reaffirmed |
| Aug 1, 2024 | Selling, general and administrative expenses | FY2024 | $1.30B | Lowered |
| Aug 1, 2024 | research and development expenses | FY2024 | $4.50B | Lowered |
| Aug 1, 2024 | Cost of sales | FY2024 | 40% – 50% | Raised |
| Aug 1, 2024 | cash and investments | FY2024 | $9.00B | Raised |
| Aug 1, 2024 | net product sales | FY2024 | $3.00B – $3.50B | Raised |
| May 2, 2024 | Capital expenditures | FY2024 | $900.00M | Reaffirmed |
| May 2, 2024 | Cost of sales | FY2024 | 35% | Reaffirmed |
| May 2, 2024 | Selling, general and administrative expenses | FY2024 | $1.30B | Lowered |
| May 2, 2024 | Year-end cash and investments | FY2024 | $9.00B | Raised |
| May 2, 2024 | research and development expenses | FY2024 | $4.50B | Lowered |
| May 2, 2024 | expected revenue | FY2024 | $4.00B | Reaffirmed |
| May 2, 2024 | net sales | FY2024 | $300.00M | Lowered |
| Feb 22, 2024 | capital expenditures | FY2024 | $900.00M | Reaffirmed |
| Feb 22, 2024 | research and development expenses | FY2024 | $4.50B | Lowered |
| Feb 22, 2024 | cost of sales | FY2024 | 35% | Reaffirmed |
| Feb 22, 2024 | selling, general and administrative expenses | FY2024 | $1.30B | Lowered |
| Feb 22, 2024 | cash and investments | FY2024 | $9.00B | Raised |
| Feb 22, 2024 | revenue | FY2024 | $4.00B | Reaffirmed |
| Nov 2, 2023 | capital expenditures | FY2023 | $900.00M | Lowered |
| Nov 2, 2023 | capital expenditures | FY2024 | $900.00M | New |
| Nov 2, 2023 | SG&A expenses | FY2024 | $1.30B | Lowered |
| Nov 2, 2023 | ending cash balance | FY2025 | $6.00B – $7.00B | New |
| Nov 2, 2023 | R&D expenses | FY2024 | $4.50B | New |
| Nov 2, 2023 | ending cash balance | FY2024 | $9.00B | Raised |
| Nov 2, 2023 | cost of sales | FY2023 | $5.00B | Raised |
| Nov 2, 2023 | full-year 2023 expenses | FY2023 | $6.30B | Raised |
| Nov 2, 2023 | R&D | FY2023 | $4.80B | Lowered |
| Nov 2, 2023 | tax expense | FY2023 | $800.00M – $1.00B | Lowered |
| Nov 2, 2023 | cost of sales as a percentage of sales | FY2024 | 35% | New |
| Nov 2, 2023 | product sales | FY2023 | $6.00B | Lowered |
| Nov 2, 2023 | sales | FY2024 | $4.00B | New |
| Aug 3, 2023 | capital expenditures | FY2023 | $1.00B | Reaffirmed |
| Aug 3, 2023 | cost of sales | FY2023 | $3.50B – $4.00B | Raised |
| Aug 3, 2023 | expenses | FY2023 | $6.00B | Raised |
| Aug 3, 2023 | R&D | FY2023 | $4.50B | Lowered |
| Aug 3, 2023 | tax benefit | FY2023 | $700.00M – $1.00B | Lowered |
| Aug 3, 2023 | COVID-19 sales | FY2023 | $6.00B – $8.00B | Raised |
| May 4, 2023 | capital investments | FY2023 | $1.00B | Reaffirmed |
| May 4, 2023 | tax benefit | FY2023 | $300.00M – $500.00M | Lowered |
| May 4, 2023 | cost of sales | Q2 FY2023 | $500.00M – $600.00M | New |
| May 4, 2023 | expenses | FY2023 | $6.00B | Raised |
| May 4, 2023 | R&D | FY2023 | $4.50B | Lowered |
| May 4, 2023 | sales | Q2 FY2023 | $200.00M – $300.00M | New |
| May 4, 2023 | minimum sales | FY2023 | $5.00B | Raised |
| May 4, 2023 | annual sales | FY2027 | $8.00B – $15.00B | New |
| Feb 23, 2023 | capital investments | FY2023 | $1.00B | New |
| Feb 23, 2023 | expenses | FY2023 | $6.00B | New |
| Feb 23, 2023 | R&D | FY2023 | $4.50B | Lowered |
| Feb 23, 2023 | Cost of sales | FY2023 | 35% – 40% | New |
| Feb 23, 2023 | COVID vaccine sales | FY2023 | $5.00B | New |
| Feb 23, 2023 | product sales | FY2023 | $2.00B | Lowered |
| Aug 3, 2022 | Capital Expenditures | FY2022 | $600.00M – $800.00M | Reaffirmed |
| Aug 3, 2022 | Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses | FY2022 | $4.00B | Reaffirmed |
| Aug 3, 2022 | Advance Purchase Agreements (APAs) | FY2022 | $21.00B | Reaffirmed |
| May 4, 2022 | Capital Expenditures | FY2022 | $600.00M – $800.00M | Reaffirmed |
| May 4, 2022 | Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses | FY2022 | $4.00B | Reaffirmed |
| May 4, 2022 | Advanced Purchase Agreements (APAs) | FY2022 | $21.00B | Narrowed |
| Feb 24, 2022 | Capital Expenditures | FY2022 | $600.00M – $800.00M | New |
| Feb 24, 2022 | Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses | FY2022 | $4.00B | New |
| Nov 4, 2021 | capital investments | FY2021 | $400.00M | New |
| Nov 4, 2021 | Cost of sales as percentage of product sales | FY2021 | 16% – 17% | New |
| Nov 4, 2021 | deliveries of its COVID-19 vaccine | FY2021 | 700 – 800 | New |
| Nov 4, 2021 | sales | FY2022 | $17.00B – $22.00B | New |
| Nov 4, 2021 | product sales | FY2021 | $15.00B – $18.00B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Moderna filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Results
- Update
- Results
- Results
- Update
- Results
- Update
- Update
- Results
- Results
- Results
See a number that looks wrong?